Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HLS Therapeutics Inc ( (TSE:HLS) ) has provided an update.
HLS Therapeutics has launched NILEMDO (bempedoic acid) across Canada, offering a first-in-class, once-daily oral non-statin therapy for adults who cannot reach LDL-cholesterol targets on existing treatments or are statin intolerant. Supported by the large CLEAR Outcomes trial, the drug demonstrated a reduction in major adverse cardiovascular events and is estimated by HLS to address an unmet need in more than half a million Canadians at risk of cardiovascular disease.
The company expects meaningful private insurance coverage for NILEMDO starting in the second quarter of 2026, with potential public reimbursement later in the year, which could enhance access and strengthen its cardiovascular franchise. Alongside Vascepa and the ongoing regulatory push for the combination pill NEXLIZET, the launch positions HLS as a leading provider of novel oral cardiovascular therapies in Canada and may improve treatment options and outcomes for high-risk patients.
The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
The score is held back primarily by ongoing net losses and soft revenue trends despite strong gross margins, while positive and improving cash generation and manageable leverage provide support. Technically, indicators point to weak momentum, and valuation remains constrained by negative earnings; the latest earnings call adds a modest positive tilt due to EBITDA growth and debt reduction but is tempered by revenue and product-growth headwinds.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a Toronto-based pharmaceutical company focused on treatments for psychiatric disorders and cardiovascular disease. The company in-licenses and commercializes innovative therapies for the Canadian market, including oral cardiovascular medicines such as Vascepa and now NILEMDO, targeting patients with unmet clinical needs.
Average Trading Volume: 10,061
Technical Sentiment Signal: Sell
Current Market Cap: C$137.6M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.